ArticlePLoS neglected tropical diseases2025
Status of human onchocerciasis transmission in the Adamaoua region of Cameroon after 20 years of ivermectin mass distribution.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comorbidities of onchocerciasis and non-communicable diseases, and determinants of continued transmission in Bafut Health District, Cameroon.BMC infectious diseases · 2026Article
- Onchocerciasis and non-communicable diseases in the Bafut Health District, Cameroon: Knowledge, attitudes, and practices towards community-directed treatment with ivermectin.PLoS neglected tropical diseases · 2026Article
- Global Epidemiology of Vector-Borne Parasitic Diseases: Burden, Trends, Disparities, and Forecasts (1990-2036).Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSignificant progress has been made in onchocerciasis control through mass distribution of ivermectin among affected human populations, fostering optimism for disease elimination. However, despite these considerable advances, the elimination of the disease remains a major challenge in many African foci. This paper describes the current situation of onchocerciasis in Adamaoua Region of Cameroon after 20 consecutive years of ivermectin mass treatment. MATERIALS AND
methodsThe study was conducted between August and September 2020 in Adamaoua Region of Cameroon. Onchocerciasis endemicity was assessed through parasitological and clinical diagnosis. Microfilarodermia and nodule prevalences assessed in 2020 were compared to those of 1998-2002 and 2010-2013 surveys using the Chi-square (X 2) statistic test.
resultsA total of 4,814 participants aged between 5 and 108 years, including 50.4% men and 49.6% women were enrolled in the study. The nodule and microfilaria prevalences reported from this sub-sample were 0.87 [0.64 - 1.19] % and 0.77 [0.54 - 1.07] %, respectively. At the community level, the mf prevalences ranged from 0.5% to 4.5%. Globally, the community microfilarial loads (CMFL) were < 0.5 mf/ss. The survey therapeutic coverage rates were between 40% and 78%, lower than those reported (79% - 83%) by the NOCP. The coverage rates in ivermectin treatment in all age groups of the population were below 65%, except for the 40-50 age group where it was ≈70%.
conclusionThe results of this study show a drastic decline in onchocerciasis prevalences after 20 consecutive years of CDTI, indicating a significant progress towards stopping O. volvulus transmission in Adamaoua Region. However, additional efforts are needed to increase the population coverage in ivermectin treatment in order to stop the parasite transmission in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.